Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer

Journal of Clinical Oncology

Volumn 25, Issue 31, 2007, Pages 4967-4973

  Deshmane, VijayaLaxmi ^a   Krishnamurthy, S ^a   Melemed, Allen S ^a   Peterson, Patrick ^a   Buzdar, Aman U ^a  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VAGINA DISCHARGE;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; PIPERIDINES; POSTMENOPAUSE; RECEPTORS, STEROID; SURVIVAL ANALYSIS; TAMOXIFEN; THIOPHENES; TIME FACTORS; TREATMENT FAILURE;

EID: 36849037462     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.5992     Document Type: Article

References (31)

1. Morello KC, Wurz GT, DeGregorio MW: SERMs: Current status and future trends. Crit Rev Oncol Hematol 43:63-76, 2002
2. Hendrick A, Subramanian VP: Tamoxifen and thromboembolism. JAMA 243:514-515, 1980
3. Lipton A, Harvey HA, Hamilton RW: Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 68:887-889, 1984
4. Nayfield SG, Gorin MB: Tamoxifen-associated eye disease: A review. J Clin Oncol 14:1018-1026, 1996
5. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1:117-120, 1989
6. Lahti E, Blanco G, Kauppila A, et al: Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81:660-664, 1993
7. Uziely B, Lewin A, Brufman G, et al: The effect of tamoxifen on the endometrium. Breast Cancer Res Treat 26:101-105, 1993
8. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537, 1994
9. van Leeuwen FE, Benraadt J, Coebergh JW, et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452, 1994
10. Barakat RR: The effect of tamoxifen on the endometrium. Oncology (Williston Park) 9:129-134, 1995
11. Rutqvist LE: Controversial issues in adjuvant systemic therapy of early breast cancer. Acta Oncol 37:421-430, 1998
12. Dhingra K: Selective estrogen receptor modulation: The search for an ideal hormonal therapy for breast cancer. Cancer Invest 19:649-659, 2001
13. Suh N, Glasebrook AL, Palkowitz AD, et al: Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res 61:8412-8415, 2001
14. Munster PN: Arzoxifene: The development and clinical outcome of an ideal SERM. Expert Opin Investig Drugs 15:317-326, 2006
15. Baselga J, Llombart-Cussac A, Bellet M, et al: Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol 14:1383-1390, 2003
16. Buzdar A, O'Shaughnessy JA, Booser DJ, et al: Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 21:1007-1014, 2003
17. Pocock S, Simon R: Sequential treatment assignment with balancing of prognostic factors in controlled clinical trials. Biometrics 31:103-115, 1975
18. WHO: Handbook for Reporting Results of Cancer Treatment. Publication No. 48. Geneva, Switzerland, World Health Organization, 1979
19. National Cancer Institute: Common Toxicity Criteria Manual (version 1.0). Bethesda, MD, National Cancer Institute, National Institute of Health, United States Department of Health and Human Services, 1982
20. Crowley J: Handbook of Statistics in Clinical Oncology. New York, NY, Marcel Dekker Inc, 2001
21. Cox DR: Regression models and life tables (with discussion). J Royal Stat Soc Series B 34:187-220, 1972
22. Kaplan EL, Meier P: Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Johnston SR, Boeddinghaus IM, Riddler S, et al: Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Cancer Res 59:3646-3651, 1999
24. Hasmann M, Rattel B, Loser R: Preclinical data for Droloxifene. Cancer Lett 84:101-116, 1994
25. Buzdar A, Hayes D, El-Khoudary A, et al: Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 73:161-175, 2002
26. Arpino G, Nair KM, Doval DC, et al: Idoxifene versus tamoxifen: A randomized comparison in postmenopausal patients with metastatic breast cancer. Ann Oncol 14:233-241, 2003
27. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741, 2006
28. Ma YL, Bryant HU, Zeng Q, et al: Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J Bone Miner Res 17:2256-2264, 2002
29. Sato M, Turner CH, Wang T, et al: LY353381.HCl: A novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 287:1-7, 1998
30. Effect of arzoxifene on bone mass and the uterus. http://clinicaltrials. gov/show/NCT00085956
31. Effects of arzoxifene on bone fractures and invasive breast cancer. http://clinicaltrials.gov/show/NCT00088010